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Introduction: Small-cell lung cancer (SCLC) is the most aggressive 
subtype of lung cancer, with no early detection strategy or targeted 
therapy currently available. We hypothesized that difference gel 
electrophoresis (DIGE) may identify membrane-associated proteins 
(MAPs) specific to SCLC, advance our understanding of SCLC biol-
ogy, and discover new biomarkers of SCLC.
Methods: MAP lysates were prepared from three SCLCs, three 
non–small-cell lung cancers, and three immortalized normal bron-
chial epithelial cell lines and coanalyzed by DIGE. Subsequent pro-
tein identification was performed by mass spectrometry. Proteins 
were submitted to Ingenuity Pathway Analysis. Candidate biomark-
ers were validated by Western blotting (WB) and immunohisto-
chemistry (IHC).
Results: Principal component analysis on the global DIGE data set 
demonstrated that the four replicates derived from each of the nine 
cell lines clustered closely, as did samples within the same histological 
group. One hundred thirty-seven proteins were differentially expressed 
in SCLC compared with non–small-cell lung cancer and immortalized 
normal bronchial epithelial cells. These proteins were overrepresented 
in cellular/tissue morphology networks. Dihydropyrimidinase-related 
protein 2, guanine nucleotide–binding protein alpha-q, laminin recep-
tor 1, pontin, and stathmin 1 were selected as candidate biomarkers 
among MAPs overexpressed in SCLC. Overexpression of all candi-
dates but RSSA in SCLC was verified by WB and/or IHC on tissue 
microarrays. These proteins were significantly associated with SCLC 
histology and survival in univariables analyses.
Conclusion: DIGE analysis of a membrane-associated subproteome 
discovered overexpression of dihydropyrimidinase-related protein 
2, guanine nucleotide–binding protein alpha-q, RUVB1, and stath-
min 1 in SCLC. Results were verified by WB and/or IHC in primary 
tumors, suggesting that investigating their functional relevance in 
SCLC progression is warranted. Association with survival requires 
further validation in larger clinical data sets.
Key Words: Biomarker, Membrane-associated, Proteomics, 
 Small-cell lung cancer.
(J Thorac Oncol. 2014;9: 324–336)
Small-cell lung cancer (SCLC) represents 10% to 15% of lung cancers and is clinically the most aggressive subtype, 
with a 5-year overall survival (OS) as low as 5%.1 Molecular 
steps leading to SCLC are still poorly understood, and this 
has translated into the absence of efficient early detection 
strategies or targeted therapies. In-depth proteomic analysis 
is therefore needed to improve our understanding of SCLC 
tumorigenesis and may have implications in the discovery 
of novel early detection and therapeutic strategies for this 
aggressive cancer.
Although (epi)genetic alterations are driving carcino-
genesis and genomic studies have provided valuable informa-
tion on cancer biology, the cellular phenotype is determined 
by proteins and cannot be predicted by genomics alone. 
Proteomic approaches are therefore powerful tools to study 
cancer biology.2,3 Among them, difference gel electrophoresis 
(DIGE) coupled with protein identification by mass spectrom-
etry (MS) is widely used in comparative proteomics for the 
detection of protein differences with high reproducibility and 
reliability.4–6 However, these studies have not identified key 
underpinnings of tumor progression or specific molecular tar-
gets for SCLC diagnostics or therapeutics.
Membrane-associated proteins (MAPs) are excel-
lent targets for diagnostic and therapeutic interventions. 
Although membrane proteins constitute only 20% to 30% of 
human proteome, they represent more than 60% of all drug 
targets.7 In this study, we hypothesized that the identification 
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of  SCLC-specific MAPs by DIGE may advance our under-
standing of SCLC biology and lead to the discovery of new 
candidate diagnostic or therapeutic biomarkers. We therefore 
analyzed MAPs from three SCLC, three non–small-cell lung 
cancer (NSCLC), and three immortalized normal bronchial 
epithelial (INBE) cell lines by DIGE.
MATERIALS AND METHODS
Cell Lines and Tissues
Nine cell lines were used for this study: National Cancer 
Institute (NCI)-H69,  NCI-H82, NCI-H209, A549, NCI-H23, 
NCI-H520, BEAS-2B, HBEC-3KT, and 16-HBE. All were pur-
chased from ATCC (Manassas, VA), except HBEC-3KT (Dr. 
Minna’s gift, University of Texas Southwestern) and 16-HBE 
(Dr. Gruenert’s gift, Children’s Hospital, Oakland Research 
Institute). They were cultured under recommended conditions.
Tissue microarrays (TMAs) made of SCLC and 
NSCLC specimens were prepared from formalin-fixed, 
 paraffin-embedded tissue blocks8 retrieved from the 
Pathology Department’s archives at Vanderbilt University 
Medical Center, Nashville VA Medical Center, and St 
Thomas Hospital in Nashville, TN. They were obtained 
between 1996 and 2008 from 136 patients who had sur-
gery or bronchoscopy. Samples were annotated with clinical 
data elements. The study was approved by the Institutional 
Review Board at each institution.
MAP Extraction
MAP extraction was performed four independent times 
for each cell line with the ProteoExtract Native Membrane 
Protein Extraction Kit (EMD Chemicals, San Diego, CA) per 
manufacturer’s protocol.
DIGE and MS
Minimal labeling was performed with 
N-hydroxysuccinimide–ester dyes Cy2/3/5 using the mixed 
internal standard methodology as described previously,9 
with 150 μg of protein of each of the 36 experimental sam-
ples. DIGE-associated instrumentation was manufactured 
by GE Healthcare (Piscataway, NJ). Isoelectric focusing 
(pH 4–7, 24 cm) was performed after passive rehydration 
with sample and then focused using a manifold-equipped 
IPGphor per manufacturer’s protocol. Second-dimensional 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
was performed using handcast gels for which one plate was 
pre-silanized using an Ettan DALT 12U per manufacturer’s 
protocol. Cy2/3/5-specific 16-bit data files were acquired at 
100-μm resolution separately by dye-specific excitation and 
emission wavelengths using a Typhoon 9400 Variable Mode 
Imager and analyzed using DeCyder_6.5 software. Gels were 
counterstained for total protein content with SyproRuby 
(Molecular Probes/Invitrogen, Grand Island, NY), followed 
by robot excision of proteins of interest and subsequent pro-
cessing for trypsin digestion and MS using an automated Spot 
Handling Workstation. Resulting peptides were subjected to 
C18 reverse-phase liquid chromatography coupled in-line 
with tandem MS using an LTQ Orbitrap tandem MS equipped 
with MicroAS autosampler and Surveyor HPLC pump, nano-
spray source, and Xcalibur_2.0 instrument control (Thermo 
Scientific, San Jose, CA). Tandem MS/MS data were searched 
against proteins extracted from UniProtKB database (www.
uniprot.org), with taxonomy tag “Homo sapiens (human)” 
acquired on July 2009 (173,736 entries). This database was 
concatenated with protein sequences in reverse to enable false 
discovery rate calculations and also contained common labo-
ratory contaminants. Searches were performed using Sequest 
and X! Tandem algorithms, allowing for cysteine carbamido-
methylation and partial methionine oxidation. Results were 
validated and assembled into protein identifications using 
Scaffold_3.1.2 (Proteome Software Inc., Portland, OR). 
Peptide identifications were accepted if they could be estab-
lished at more than 95.0% probability as specified by Peptide 
Prophet algorithm.10 Protein identifications were accepted if 
they could be established at more than 99.0% probability and 
contained two or more identified peptides. Protein probabili-
ties were assigned by Protein Prophet algorithm.11 Proteins 
containing similar peptides and not differentiated based on 
MS/MS alone were grouped to satisfy parsimony principles.
Ingenuity Pathway Analysis
Biological processes, molecular functions, and genetic/
protein networks of identified proteins were analyzed using 
Ingenuity Pathway Analysis (IPA) tools (Ingenuity Systems, 
Mountain View, CA). The score associated with a particular 
network was the likehood of differentially expressed proteins 
being found together due to chance.
Western Blotting
Blots were probed with antibodies against human v-Akt 
murine thymoma viral oncogene homolog 1 (AKT) (1:1000; 
Cell Signaling, Danvers, MA),  dihydropyrimidinase-related 
protein 2 (DPYL2) (1:1000; LSBio, Seattle, WA), phospho-
DPYL2 (Thr514/Ser518) (1:1000; LSBio), E-cadherin (1:1000; 
BD Transduction Laboratories, San Jose, CA), endothe-
lial growth factor receptor (EGFR) (1:750; Santa Cruz 
Biotechnology, Santa Cruz, CA), guanine nucleotide–binding 
protein alpha-q (GNAQ) (1:900; Abcam, Cambridge, MA), 
neural cell adhesion molecule (NCAM) (1:500; Sigma, St. 
Louis, MO), laminin receptor 1 (RSSA) (1:1000; Sigma), pon-
tin (RUVB1) (1:1000; Atlas Antibodies, Stockholm, Sweden), 
stathmin 1 (STMN1) (1:1000; Cell Signaling), and phospho-
STMN1 (Ser16) (1:1000; Cell Signaling). Protein expression 
was normalized to Actin (1:5000; Sigma).
Immunohistochemistry
Tissue sections were stained following previously 
reported protocol,12 using antibodies against human DPYL2 
(1:500; LSBio), GNAQ (1:100; Abcam), RSSA (1:150; 
LSBio), RUVB1 (1:100; Atlas Antibodies), and STMN1 
(1:50; Cell Signaling). Staining intensity of cases represented 
in triplicate was evaluated by two independent observers 
(B.W., S.O.) as follows: 0, no staining; 1, weak; 2, moder-
ate; and 3, strong. Staining intensity was then multiplied by 
stained tumor cell percentage to obtain the final staining score 
(range, 0–300).
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Statistics
DIGE.  In DeCyder_6.5, the normalized volume ratio of each 
protein spot feature from a Cy3- or Cy5-labeled sample was 
quantified relative to the Cy2 signal from the pooled-sample 
internal standard corresponding to the same spot feature, and 
all ratios were normalized across all 18 DIGE gels using the 
individual signals from the Cy2-labeled standard. Univariable 
analyses (Student’s t test and analysis of variants) were used 
to establish confidence associated with expression changes. 
Multivariate principal components analysis and hierarchical 
clustering (using Euclidean correlation and average linkage) 
were used to assess global variation arising from individual 
samples.
iPA. One-side right-tailed Fisher’s exact test (α = 0.05) was 
used to calculate the significance of the values assigned to the 
analyzed functions of proteins.
Immunohistochemistry. Wilcoxon rank-sum or Kruskal-Wal-
lis tests were used to correlate average staining scores with 
categorical clinical outcomes, and Spearman’s rank correla-
tion was used for continuous outcomes. OS was calculated 
from the date of diagnosis to the date of death or last date of 
contact for those alive at the time of analysis. Descriptive sta-
tistics, including median and interquartile ranges for continu-
ous and percentages or frequencies for categorical variables, 
were reported. Multivariable analyses were performed using 
Cox proportional hazards model to adjust for age, pack years, 
histology, and stage. All tests were two-sided, and p values less 
than 0.05 were considered statistically significant. Analyses 
were performed using R_2.15.1.
RESULTS
Identification by DIGE of 137 Proteins 
Differentially Expressed in SCLC
We extracted MAPs from three SCLC (NCI-H69, 
NCI-H82, NCI-H209), three NSCLC (A549, NCI-H23, 
 NCI-H520), and three INBE (BEAS-2B, HBEC-3KT, 
16-HBE) cell lines in quadriplicate, obtaining 36 extracts. 
By Western blotting (WB), membrane proteins E-cadherin, 
NCAM, and EGFR were mainly expressed in membrane-
associated, while cytosolic protein AKT was mainly expressed 
in cytosolic extracts (Fig. 1). This confirmed enrichment for 
MAPs in MAP extracts.
MAP extracts were analyzed by DIGE according to 
the experimental design summarized in Supplementary table 
1 (Supplemental Digital Content 1, http://links.lww.com/
JTO/A529). On each of the 18 gels used, many differentially 
expressed protein spots were observed (representative DIGE 
image in Supplementary figure 1, Supplemental Digital Content 
2, http://links.lww.com/JTO/A530). Principal components anal-
ysis on the global data set demonstrated that the four replicates 
derived from each of the nine cell lines clustered very closely 
by global expression patterns, as did samples within each clas-
sification (12 samples per classification) using the first three 
principle components (cumulative variance = 62%; Fig. 2A).
For further analyses, we selected 135 DIGE protein 
spots significantly over/underexpressed in SCLC compared 
with NSCLC and INBE cells (p < 10−3) (Fig. 2B). These pro-
tein spots were digested into peptides for tandem MS analy-
sis, and 137 unique proteins were identified. Among them, 
83 were from overexpressed (Table 1) and 54 from underex-
pressed spots (Supplementary table 2, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A529).
Overrepresentation in SCLC of 
Proteins Involved in Cellular/
Tissue Morphology Networks
Using IPA, we found that the 137 proteins differen-
tially expressed in SCLC were overrepresented in five spe-
cific networks: (1) gene expression, cellular response to 
therapeutics, cellular assembly, and organization (score: 60); 
(2) protein synthesis, RNA post-transcriptional modification, 
gene expression (score: 49); (3) cell death, cellular assembly 
and organization, cellular function, and maintenance (score: 
47); (4) carbohydrate metabolism, small molecule biochem-
istry, DNA replication, recombination, and repair (score: 29); 
and (5) hematological system development/function, humoral 
immune response, tissue morphology (score: 23). Proteins 
related to cellular assembly, organization, and morphology 
and tissue morphology (Table 3) were overrepresented in three 
of these five networks, the most interesting one being the cell 
death, cellular assembly, organization, function, and mainte-
nance network (Supplementary figure 2, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A531). Many proteins 
represented in these three networks were underexpressed in 
SCLC (Table 4). Among proteins represented in these top 
five networks and overexpressed in SCLC, we found proteins 
FIGURE 1.  Isolation of membrane-associated pro-
teins. Membrane-associated (mbr) and cytosolic (cyto) 
extracts were resolved with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, and blots were incu-
bated with anti-E-cadherin, NCAM, EGFR, AKT, or actin 
antibodies. E-cadherin, NCAM, EGFR, and AKT levels 
were normalized to actin. In each quadruplicate analysis, 
membrane proteins E-cadherin, NCAM, and EGFR were 
mainly expressed in membrane-associated extracts, 
whereas cytosolic protein AKT was mainly expressed in 
cytosolic extracts. Blots are representative of three inde-
pendent experiments. AKT, v-Akt murine thymoma viral 
oncogene homolog 1; EGFR, epidermal growth factor 
receptor; NCAM, neural cell adhesion molecule.
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related to the nervous system (Table 5) and involved in inhi-
bition of apoptosis and induction of proliferation and motil-
ity (Supplementary table 3, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A529).
The top biological functions of the proteins differen-
tially expressed in SCLC were also determined using IPA 
(Supplementary table 4, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A529). Consistent with the network 
analysis, we found that the functions of these proteins were 
related to the cytoskeleton, morphology, and interactions with 
the environment and to the neuroendocrine system, cell cycle, 
growth, apoptosis, and metabolism.
Selection of DPYL2, GNAQ, RSSA, RUVB1, 
and STMN1 as SCLC Candidate Biomarkers
To select SCLC candidate biomarkers among the 137 pro-
teins differentially expressed in SCLC, we used three criteria: 
(1) proteins overexpressed in SCLC (N = 81), (2) confirmed 
FIGURE 2.  DIGE results. A, PCA of the DIGE global data set. The axes correspond to the first three principal components. 
The apparent groups yielded by PCA are enclosed in circles: blue circle for immortalized normal bronchial epithelial cell 
lines (normal), green circle for NSCLC cell lines, and red circle for SCLC cell lines. The four replicates from each of the nine 
cell lines clustered very closely, as did samples within each histological subgroup. B, C, Quantitative analysis of protein 
expression in the nine cell lines analyzed by DIGE. Representative graphs of protein features significantly overexpressed (B) 
and underexpressed (C) in SCLC compared with immortalized normal bronchial epithelial and NSCLC cell lines (p < 10−3). 
The Y axis represents the standardized log protein abundance generated by the DeCyder analysis. DIGE, difference gel 
electrophoresis; NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; PC, principle component; PCA, principal 
component analysis.
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TABLE 1.  Proteins Overexpressed in Small-Cell Lung Cancer, Membrane-Associated, and with Functions Relevant to Cancer 
Progression and/or Neuroendocrine Phenotype and/or Part of Networks Related to Cell/Tissue Morphology
Protein Symbol Gene Symbol
Overexpressed in 
SCLC (N = 83)
Membrane- 
Associated  
(N = 32)
Interesting Functions for SCLC Progression  
(N = 17)
Final Candidate 
Biomarkers  
(N = 5)Av. Ratio t test
Relevant 
to Cancer 
Progression
Relevant to 
Neuroendocrine 
Phenotype
Part of Cell/Tissue 
Morphology 
Networks
PRDX2 PRDX2 7.23 2.90E−11 x x x
STMN1 STMN1 5.71 1.30E−12 x x x x x
HNRPC HNRNPC 5.38 8.90E−10
FPPS FDPS 4.68 1.80E−09
STRAP STRAP 4.68 1.80E−09 x x
PSA1 PSMA1 4.18 3.10E−12
ATD3A ATAD3A 3.92 4.90E−09 x
ERO1A ERO1L 3.92 4.90E−09 x
G3BP1 G3BP1 3.92 4.90E−09 x
HSP71 HSPA1A-1B 3.92 4.90E−09
MIR7-1 3.92 4.90E−09
HMGB1 HMGB1 3.67 6.90E−07
CALD1 CALD1 3.55 1.80E−09 x x x
SPF27 BCAS2 3.44 8.50E−13
ROAA HNRNPAB 3.31 1.70E−08
CAPG CAPG 3.06 2.40E−09 x x
RS10 RPS10 3.06 5.90E−05
DPYL2 DPYSL2 2.73 4.10E−08 x x x x x
TCPG CCT3 2.73 4.10E−08
AL9A1 ALDH9 2.72 4.50E−10
EFR1 ERVFRDE1 2.72 4.50E−10 x
IF2B EIF2S2 2.72 4.50E−10
ODO2 DLST 2.72 4.50E−10 x
PTBP1 PTBP1 2.72 4.50E−10
RUVB2 RUVBL2 2.72 4.50E−10 x x
SPF45 RBM17 2.72 4.50E−10
UAP56 BAT1 2.72 4.50E−10
BUB3 BUB3 2.71 2.50E−08
PCBP1 PCBP1 2.71 2.50E−08
RBM4B RBM4B 2.71 2.50E−08
RSSA RPSA 2.71 2.50E−08 x x x x x
EIF3H EIF3H 2.69 3.10E−10
AHNK AHNAK 2.64 2.40E−07
HSP7E HSPA14 2.64 2.40E−07
IF5 EIF5 2.64 2.40E−07
SFRS6 SFRS6 2.64 2.40E−07
TCPQ CCT8 2.64 2.40E−07
ARP2 ACTR2 2.62 1.40E−06
PURA PURA 2.62 1.40E−06
AMPL LAP3 2.61 4.20E−09
CSTF1 CSTF1 2.61 4.20E−09
ODB2 DBT 2.61 4.20E−09
RUVB1 RUVBL1 2.61 4.20E−09 x x x
CT007 C20orf7 2.56 6.00E−05 x
OCAD1 OCIAD1 2.42 2.80E−05
SYYC YARS 2.39 2.80E−05
(Continued)
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membrane-associated (N = 32) (including 10 plasma membrane, 
12 endomembrane, and 10 MAPs), and (3) with functions rel-
evant to cancer progression and/or neuroendocrine phenotype 
and/or part of networks related to cell/tissue morphology (Table 
1). Five proteins met these criteria: DPYL2, GNAQ, RSSA, 
RUVB1, and STMN1 (main functions reported on Table 2).
To verify the expression of our candidates, we analyzed 
the MAP lysates initially used for DIGE by WB. Although 
there was no expression difference among SCLC, NSCLC, 
and INBE cells for RSSA and RUVB1, we confirmed 
DPYL2, GNAQ, and STMN1 overexpression in SCLC (Fig. 
3A). Moreover, we found phospho-DPYL2 (Thr514/Ser518) and 
phospho-STMN1 (Ser16) overexpression in SCLC, suggest-
ing the activation of DPYL2 and STMN1 in SCLC (Fig. 3).
Next, we performed immunohistochemistry (IHC) 
on TMAs made of 100 NSCLCs and 36 SCLCs. Protein 
FUBP2 KHSRP 2.29 0.00059
DNJC3 DNAJC3 2.14 6.20E−07
GLSK GLS 2.14 6.20E−07
PRDX4 PRDX4 2.14 9.50E−06 x x
PRP19 PRPF19 2.14 6.20E−07
ARSA1 ASNA1 2.1 3.80E−08 x
FKBP8 FKBP8 2.03 6.30E−08 x x x
HNRH1 HNRNPH1 2.03 6.30E−08
TBB5 TUBB 2.03 6.30E−08 x x
CH60 HSPD1 1.97 2.60E−05 x x x
NONO NONO 1.97 2.60E−05
SF3A3 SF3A3 1.97 2.60E−05
TBL1R TBL1XR1 1.97 2.60E−05
TPR TPR 1.92 0.0006 x x
ACTB ACTB 1.9 2.60E−06
RANG RANBP1 1.9 2.60E−06
ACON ACO2 1.83 3.40E−05
EFG2 GFM2 1.83 3.40E−05
IMMT IMMT 1.83 3.40E−05 x
MIRO2 RHOT2 1.83 3.40E−05 x
PLOD3 PLOD3 1.83 3.40E−05 x x
XRCC5 XRCC5 1.83 3.40E−05 x
CORO1A CORO1A 1.82 2.80E−05 x x x
DLDH DLD 1.82 2.80E−05
SCOT1 OXCT1 1.82 2.80E−05
EIF3G EIF3G 1.81 6.00E−07
SCMC1 SLC25A24 1.81 6.00E−07 x
TADBP TARDBP 1.81 6.00E−07
GNAQ GNAQ 1.75 2.50E−05 x x x x x
IDH3B IDH3B 1.75 2.50E−05
UBFD1 UBFD1 1.75 2.50E−05
RBBP7 RBBP7 1.73 0.0056
ATPB ATP5B 1.65 4.90E−05 x
TPD52 TPD52 1.65 0.00054 x
KAP2 PRKAR2A 1.62 0.00062 x
PDIA6 PDIA6 1.62 0.00062 x
PCBP2 PCBP2 1.56 3.80E−06
SCLC, small-cell lung cancer.
Bold indicates candidate biomarkers.
TABLE 1.  (Continued)
Protein Symbol Gene Symbol
Overexpressed in 
SCLC (N = 83)
Membrane- 
Associated  
(N = 32)
Interesting Functions for SCLC Progression  
(N = 17)
Final Candidate 
Biomarkers  
(N = 5)Av. Ratio t test
Relevant 
to Cancer 
Progression
Relevant to 
Neuroendocrine 
Phenotype
Part of Cell/Tissue 
Morphology 
Networks
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expression was membranous and cytosolic for DPYL2, 
GNAQ, and STMN1 and cytosolic for RSSA and RUVB1. 
Median staining scores in NSCLC and SCLC, respec-
tively, were 180 (range, 50–300) and 300 (range, 60–300) 
for DPYL2 (p < 0.001), 80 (range, 0–300) and 250 (range, 
30–300) for GNAQ (p < 0.001), 100 (range, 0–300) and 150 
(range, 0–300) for RSSA (p = 0.051), 28 (range, 0–300) 
and 180 (range, 0–200) for RUVB1 (p < 0.001), and 0 
(range, 0–240) and 240 (range, 0–300) for STMN1 (p 
< 0.001). Thus, IHC on TMAs verified overexpression in 
SCLC of all candidate biomarkers but RSSA. STMN1 was 
strongly expressed in SCLCs, whereas it was absent in most 
NSCLCs. Representative images of NSCLC and SCLC tis-
sues with staining scores close to average staining scores for 
each biomarker in each histological subgroup are displayed 
in Figure 4.
Correlation of the Candidate Biomarkers’ 
Expression with Clinical Characteristics
Results of the correlations between the candidate bio-
markers’ staining scores and various clinical characteristics 
in univariable analyses are presented in Table 6. In these uni-
variable analyses, staining scores were significantly higher 
in SCLC than in NSCLC for DPYL2, GNAQ, RUVB1, and 
STMN1 (p < 0.001). OS was significantly shorter in the pres-
ence of higher staining scores for DPYL2 (p = 0.022), GNAQ 
(p = 0.026), RUVB1 (p = 0.024), and STMN1 (p = 0.001). 
However, these were not associated with OS after tumors were 
broken by histology.
In multivariable analyses including each biomarker’s 
average staining score, lung cancer histology, disease stage, 
age, sex, and smoking status, we did not confirm the associa-
tion between staining scores and OS (Table 7). However, age 
was an independent predictor of OS (nonlinear trend) for all 
biomarkers. For the subset of 36 SCLCs, we did not find a sig-
nificant association between staining scores and OS in multi-
variable analyses including each biomarker’s average staining 
score, disease stage, and age (Table 8).
DISCUSSION
The main objective of this study was to test the hypoth-
esis that the identification of MAPs specific to SCLC by DIGE 
may advance our understanding of SCLC biology and lead to 
the discovery of new candidate biomarkers of SCLC. To do 
so, we analyzed a membrane-associated subproteome in three 
SCLC, three NSCLC, and three INBE cells by DIGE and vali-
dated these results in primary SCLCs.
DIGE is a proteomic tool widely used to study can-
cer biology. In a previous study, DIGE analysis of 30 lung 
cancer cell lines including SCLCs, SqCCs, and ADCs led to 
the discovery of a 32-protein spots signature able to distin-
guish between the three histological types, further validated 
in tissues (29 NSCLCs and 1 SCLC).6 Other DIGE studies 
found proteins overexpressed in SCLC when compared with 
control cells13 or normal bronchial epithelium tissues.14 Only 
one DIGE study specifically analyzed MAPs in the SCLC cell 
line H69 and its doxorubicin-resistant subcell line H69AR and 
found, in H69AR, upregulation of Serca2, a calcium pump 
located in the endoplasmic reticulum membrane.15
In our DIGE analysis, replicates from each cell line clus-
tered very closely, demonstrating low technical noise and high 
reproducibility in membrane fractionation. Samples within each 
histological group also clustered very closely, indicating that 
many variations were descriptive of differences between classi-
fications. Further analyses revealed 135 distinct protein features 
differentially expressed in SCLC when compared with NSCLC 
and INBE cells, including 137 proteins. These were overrep-
resented in the cellular assembly, organization, morphology, 
and tissue morphology networks. Among proteins represented 
in these networks and underexpressed in SCLC, many were 
involved in cell–cell and cell–extracellular matrix interactions. 
This was consistent with the nonadherent phenotype that many 
SCLC cells have in vitro (including these in this study). Among 
proteins part of these networks and overexpressed in SCLC, there 
were proteins involved in nerve/brain development and endo-
crine functions, according to the neuroendocrine nature of SCLC 
cells and previous proteomic studies.13 Many proteins were 
involved in cell cycle, growth, apoptosis, and metabolism, which 
TABLE 2.  Subcellular Location and Functions of the Final Candidate Biomarkers
Protein 
Symbol Subcellular Location Interesting Functions for SCLC Progression
STMN1 Cytosolic MAP Role in cell cycle progression and migration through microtubule depolymerization
Possible role in axon formation during neurogenesis and neuron polarization
Overexpression plays a role in tumor progression in various cancers, and contributes to chemoresistance
DPYL2 PMP and cytosolic MAP Role in neuronal differentiation, axon guidance, neuronal growth, and cell migration in developing nervous system
Associated with various neuropathologic or psychiatric disorders but not with cancer
RSSA PMP (mainly), cytosolic and 
nuclear
Laminin receptor, role in cell adhesion to basal membrane and activation of signaling transduction pathways
Overexpression correlated with invasive phenotype in various cancers
RUVB1 Nuclear (mainly) and PMP AAA+ ATPase interacting with several transcription factors involved in carcinogenesis
Role in tumor invasion by binding plasminogen at cell surface and increasing its activation into plasmin
Overexpression observed in many cancers
GNAQ PMP and cytosolic MAP Couples cell surface transmembrane receptors to intracellular signaling pathways, including the MAPK pathway
Activating mutations described in melanoma
MAP, membrane-associated protein; PMP, plasma membrane protein; SCLC, small-cell lung cancer.
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were also consistent with SCLC aggressive behavior. DPYL2, 
GNAQ, RSSA, RUVB1, and STMN1 were selected as candidate 
biomarkers among MAPs overexpressed in SCLC and with cel-
lular functions relevant to cancer progression (all of them) and/or 
the neuroendocrine phenotype (GNAQ, DPYL2, and STMN1), 
and/or part of networks related to cell/tissue morphology (all of 
them but RUVB1). Our ultimate goal was to find molecular tools 
to move our discoveries toward SCLC molecular imaging or tar-
geted therapies. Interestingly, overexpression of DPYL2, GNAQ, 
RUVB1, and STMN1 in SCLC was verified by WB and/or IHC 
on TMAs, supporting their potential as targets in SCLC.
In our DIGE analysis, STMN1 was the most signifi-
cantly overexpressed protein in SCLC cell lines. By IHC, 
STMN1 was also strongly expressed in most SCLC tissues, 
while the expression was absent in most NSCLCs and very low 
in the remaining minority. Moreover, in IPA, STMN1 was part 
of molecular networks related to cellular/tissue morphology. 
STMN1 is a membrane-associated phosphoprotein playing a 
role in cell cycle progression and migration through microtu-
bule depolymerization.16,17 STMN1 phosphorylation at Ser16 
may also be required for axon formation during neurogene-
sis and neuron polarization, which is relevant for cells with 
TABLE 3.  Proteins Related to Cellular Assembly, Organization, Morphology, and Tissue Morphology (Including Proteins Related 
to Nervous System) in the Top Five Networks in Ingenuity Pathway Analysis
Protein Symbol Function p Number of Proteins
ACTN4, HMGB1, HSP71, K1C18, PRDX2, 
PSA, PTBP1, ROAA, STMN1, TMOD3, 
TPD52, TPR, VIME, VINC
Cell morphology 0.000079 14
ACTB, ACTN4, ARP2, CALD1, CH60, 
CORO1A, CRC8, HMGB1, NPM, STMN1, 
TBB5, TMOD3, VIME, VINC, SYYC
Cell motility 0.0362 15
CAPG, CORO1A, CRC8, DPYL2, GNAQ, 
PTBP1, VINC
Shape change of cells 0.0439 7
CRC8, DPYL2 Cell blebbing 0.0123 2
CAPG, VINC Biogenesis of plasma membrane projections 0.0273 2
CALD1 Quantity of podosomes 0.00633 2
CALD1, CRC8 Formation of podosomes 0.00633 2
PTBP1, VINC Cell spreading 0.0412 2
CALD1, GNAQ, VIME Contraction of cells 0.0314 3
STMN1, VIME Quantity of microtubules 0.0123 2
DPYL2, STMN1, TBB5 Assembly of microtubules 0.00468 3
STMN1, TBB5 Polymerization of microtubules 0.0199 2
RRBP1, TBB5 Organization of microtubules 0.0159 2
CORO1A, K1C18, RRBP1, TBB5 Organization of filaments 0.0299 4
CRC8, K1C18, STMN1 Stabilization of filaments 0.0131 3
ACTN4 Elongation of actin filaments 0.0397 1
K1C18, VIME Quantity of intermediate filaments 0.0397 1
VIME Assembly of intermediate filaments 0.0397 1
K1C18 Organization and stabilization of keratin filaments 0.0161 1
VINC Organization of zonula adherens, junctions and complexes integrity 0.0161 1
CALD1, PTBP1 Size of focal adhesions 0.00175 2
HSP71 Reformation of focal adhesions 0.00806 1
CRC8 Formation of cell-matrix contacts, (de)branching of actin filaments 0.0161 1
RSSA Cell adhesion 0.0474 1
GNAQ Remodeling of neurons 0.0474 1
DPYL2 Induction of axons and formation of supernumerary axons 0.00806 1
VIME Loss of synapse 0.0474 1
FKBP8 Morphology of neural tube 0.024 1
VINC Development of spinal nerve 0.00806 1
STIP1 Neuritogenesis of hippocampal neurons 0.0397 1
ACTB, β actin; ACTN4, actinin alpha 4; ARP2, actin-related protein 2; CALD1, caldesmon 1; CAPG, capping protein (actin filament), gelsolin-like; CH60, 60 kDa chaperonin; 
COR1A, coronin 1A; CRC8, cortactin; DPYL2, dihydropyrimidinase-related protein 2; FKBP8, FK506-binding protein 8; GNAQ, guanine nucleotide–binding protein alpha-q; 
HMGB1, high mobility group box 1; HSP71, heat shock 70 kDa protein 1A; K1C18, cytokeratin 18; NPM, nucleophosmin; PRDX2, peroxiredoxin 2; PSA, puromycin-sensitive 
aminopeptidase; PTBP1, polypyrimidine tract–binding protein 1; ROAA, heterogeneous nuclear ribonucleoprotein A/B; RRBP1, ribosome-binding protein 1; RSSA, laminin receptor 
1; STIP1, stress-induced-phosphoprotein 1; STMN1, stathmin 1; SYYC, tyrosyl-tRNA synthetase; TBB5, tubulin β5; TMOD3, tropomodulin 3; TPD52, tumor protein D52; TPR, 
translocated promoter region—to activated MET oncogene; VIME, vimentin; VINC, vinculin.
Bold indicates candidate biomarkers.
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neuroendocrine differentiation. STMN1 overexpression plays a 
role in tumor progression and metastasis in various cancers and 
contributes to chemoresistance.18 Therefore, STMN1 appears 
as an attractive therapeutic target candidate. Recent integra-
tive genome analyses showed high STMN1 gene expression 
levels in 15 SCLC tumors,19 confirming our data adequately. 
Although STMN1 protein expression was absent in most of 
the NSCLC tissues we tested, previous studies demonstrated 
STMN1 overexpression in lung ADC and SqCC.20,21 However, 
consistent with our results, other studies described higher 
STMN1 expression in SCLC than NSCLC.22,23 Moreover, by 
WB, we showed higher STMN1 phosphorylation in SCLC than 
NSCLC and INBE cells, suggesting the activation of STMN1 
in SCLC and a potential role in SCLC progression. STMN1 
expression in NSCLC and SCLC was not found to be an inde-
pendent predictor of OS. This is in contrast with observations 
made in other cancers18 and may be explained by the relative 
small number of SCLCs studied here (N = 36).
DPYL2 plays a role in neuronal differentiation, axon guid-
ance, neuronal growth, and cell migration in the developing ner-
vous system,24 which is once again relevant for SCLC. DPYL2 
has been associated with various neuropathologic or psychiatric 
disorders24 but never with cancer, even though the gene is located 
in 8p, an oncogene- and tumor suppressor gene-rich region.25 
This is therefore the first report of its overexpression in SCLC. 
Moreover, we demonstrated higher DPYL2 phosphorylation in 
SCLC than NSCLC and INBE cells, suggesting DPYL2 activa-
tion in SCLC and its possible role in SCLC progression.
GNAQ is a membrane and membrane-bound protein 
from the family of guanine nucleotide–binding proteins that 
couple cell surface transmembrane receptors to intracellular 
signaling pathways, including the mitogen activated protein 
kinase (MAPK) pathway. Activating mutations of GNAQ have 
been described in melanoma, rendering them potentially sus-
ceptible to mitogen-activated protein kinase kinase kinase 1, E3 
ubiquitin protein ligase (a kinase in the MAPK pathway) inhi-
bition26,27 but have not been found in other tumors and particu-
larly not in lung cancer.28 GNAQ overexpression in SCLC has 
never been reported before and deserves further investigation.
Finally, RUVB1 is an AAA+ ATPase interacting with 
several transcription factors involved in carcinogenesis, such 
TABLE 5.  Proteins Related to the Nervous System in the Top 
Five Networks in Ingenuity Pathway Analysis
Protein Symbol Function p
GNAQ Remodeling of neurons 0.0474
DPYL2 Induction of axons and formation of 
supernumerary axons
0.00806
VIME Loss of synapse 0.0474
FKBP8 Morphology of neural tube 0.024
VINC Development of spinal nerve 0.00806
STIP1 Neuritogenesis of hippocampal neurons 0.0397
DPYL2, dihydropyrimidinase-related protein 2; FKBP8, FK506-binding 
protein 8; GNAQ, guanine nucleotide–binding protein alpha-q; STIP1, stress-induced-
phosphoprotein 1; VIME, vimentin; VINC, vinculin.
Bold indicates candidate biomarkers.
TABLE 4.  Proteins Overrepresented in the Cellular Assembly, 
Organization, Morphology, and Tissue Morphology Networks 
and Downregulated in Small-Cell Lung Cancer Cell Lines
Protein Symbol Function
ACTN4 Elongation of actin filaments
Cellular adhesion
CRC8 Debranching and branching of actin filaments
Cell blebbing
Formation of podosomes and of cell-matrix contacts
K1C18 Organization and stabilization of keratin filaments
TMOD3 Cell morphology
VIME Contraction of cells
Quantity of microtubules
Quantity and assembly of intermediate filaments
VINC Organization of zonula adherens and adherens junctions
Integrity of junctional complexes
Formation of membrane projections and cell spreading
ACTN4, actinin alpha 4; CRC8, cortactin; K1C18, cytokeratin 18; TMOD3, 
tropomodulin 3; VIME, vimentin; VINC, vinculin.
FIGURE 3.  Verification of the candidate biomarkers’ expres-
sion by Western blotting. Membrane-associated protein lysates 
were resolved with sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, and blots were incubated with an antibody 
against DPYL2, phospho-DPYL2 (Thr514/Ser518), GNAQ, RSSA, 
RUVB1, STMN1, or phospho-STMN1 (Ser16). Expression levels 
were normalized to actin. Overexpression of DPYL2, GNAQ, 
and STMN1 was observed in SCLC compared with immortal-
ized normal bronchial epithelial (normal) and NSCLC cell lines, 
while RSSA and RUVB1 expression was similar in all the cell 
lines. Increased phosphorylation of DPYL2 and STMN1 was 
also observed in SCLC compared with normal and NSCLC cell 
lines, suggesting an activation of DPYL2 and STMN1 in SCLC. 
DPYL2, dihydropyrimidinase-related protein 2; GNAQ, guanine 
nucleotide–binding protein  alpha-q; NSCLC, non–small-cell 
lung cancer; RSSA, laminin receptor 1; RUVB1, pontin; SCLC, 
small-cell lung cancer; STMN1, stathmin 1.
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as c-MYC.29 RUVB1 localized at cell surface may also be 
able to bind plasminogen and increase its activation into plas-
min,30 which plays a role in tumor invasion. RUVB1 over-
expression has been observed in many cancers, including 
NSCLC.31 However, this is the first report of RUVB1 overex-
pression in SCLC, especially when compared with NSCLC. 
Although RUVB1 expression has been correlated with poor 
outcome in colorectal carcinoma,32 we did not confirm this 
correlation with OS in our study. Small molecule inhibitors 
of RUVB1 have recently been developed, are commercially 
available,33 and will facilitate testing the functional implica-
tions of RUVB1.
Among the five SCLC candidate biomarkers we selected 
by DIGE, the only one for which we did not verify the overex-
pression in SCLC when compared with NSCLC was RSSA, a 
laminin receptor mainly localized at the surface of the plasma 
membrane. RSSA plays a role in cell adhesion to the basal mem-
brane and the consequent activation of signaling transduction 
FIGURE 4.  Verification of the candidate biomarkers’ expression by immunohistochemistry: representative cases of 130 studied 
NSCLC and 36 studied SCLC. Tissue sections were incubated with an antibody against DPYL2, GNAQ, RSSA, RUVB1, or STMN1. 
A–J, Representative images of NSCLC and SCLC tissues with a staining score close to the average staining score for each 
biomarker in each histological subgroup. A, NSCLC tumor with a DPYL2 staining score of 200. B, SCLC tumor with a DPYL2 
staining score of 300. C, NSCLC tumor with a GNAQ staining score of 100. D: SCLC tumor with a GNAQ staining score of 300. 
E, NSCLC tumor with an RSSA staining score of 100. F, SCLC tumor with an RSSA staining score of 100. G, NSCLC tumor with 
an RUVB1 staining score of 100. H, SCLC tumor with an RUVB1 staining score of 200. I, NSCLC tumor with an STMN1 stain-
ing score of 0. J, SCLC tumor with an STMN1 staining score of 300 (magnification: ×10 in the large windows and ×40 in the 
small windows; scale bars: 100 μm in the large windows and 20 μm in the small windows). DPYL2, dihydropyrimidinase-related 
protein 2; GNAQ, guanine nucleotide–binding protein alpha-q; NSCLC, non–small-cell lung cancer; RSSA, laminin receptor 1; 
RUVB1, pontin; SCLC, small-cell lung cancer; STMN1, stathmin 1.
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TABLE 6.  Patient Characteristics and Statistical Significance of the Association with DPYL2, GNAQ, RSSA, RUVB1, and STMN1 
Staining Scores in Univariables Analyses
n (%) IQR 95% CI
p
DPYL2 GNAQ RSSA RUVB1 STMN1
Sex
  Male 78 (57) 0.583 0.236 0.22 0.211 0.258
  Female 58 (43)
Race
  Caucasian 126 (93) 0.240 0.222 0.422 0.949 0.857
  African American 10 (7)
Age at diagnosis
  Median, yr 67 (58–73) 0.358 0.710 0.278 0.646 0.897
   ≤60 45 (33) 0.740 0.475 0.760 0.713 0.852
   >60 91 (67)
Smoking status
  Current smoker 45 (33) 0.689 0.408 0.633 0.059 0.071
  Ex smoker 85 (63)
  Never smoker 5 (4)
Smoking history
  Median pack year 50 (35–75) 0.301 0.163 0.659 0.643 0.231
Lung cancer histology
  NSCLC 100 (74) <0.001 <0.001 0.051 <0.001 <0.001
  SCLC 36 (26)
NSCLC histology
  ADC 49 (36) 0.006 <0.001 0.541 0.947 0.184
  SqCC 42 (31)
SCLC path stage
  Limited 24 (67) 0.262 0.687 0.378 0.309 0.240
  Extensive 12 (33)
NSCLC path stage
  I 65 (66) 0.072 0.126 0.209 0.813 0.009
  II 13 (13)
  III 17 (17)
  IV 3 (3)
Overall survival
  Median, yr 2.7 (1.9–4.0) 0.022 0.026 0.651 0.024 0.001
  Alive at 3 yr 66 (49) 0.594 0.072 0.392 0.189 0.017
SCLC overall survival
  Median, yr 1.1 (0.7–2.3) 0.466 0.427 0.643 0.778 0.705
  Alive at 3 yr 9 (25) 0.779 0.102 0.955 0.576 0.415
NSCLC overall survival
  Median, yrs 4.0 (2.6–5.6) 0.134 0.763 0.312 0.947 0.801
  Alive at 3 yrs 57 (57) 0.139 0.64 0.103 0.624 0.863
ADC overall survival
  Median, yr 4.4 (2.5–5.8) 0.295 0.926 0.678 0.543 0.642
  Alive at 3 yr 31 (63) 0.502 0.610 0.848 0.922 0.749
SqCC overall survival
  Median, yr 3.9 (2.4–5.7) 0.147 0.855 0.146 0.504 0.862
  Alive at 3 yr 23 (55) 0.082 0.345 0.017 0.176 0.946
ADC, adenocarcinoma; CI, confidence interval; DPYL2, dihydropyrimidinase-related protein 2; GNAQ, guanine-nucleotide-binding protein alpha-q; IQR, interquartile range; 
NSCLC, non–small-cell lung carcinoma; RSSA, laminin receptor 1; RUVB1, pontin; SCLC, smallcell lung carcinoma; SqCC, squamous cell carcinoma; STMN1, stathmin 1.
Bold indicates statistically significant P values.
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pathways. Its overexpression in many cancers,34–36 including 
NSCLC and SCLC,37 has already been described. A correla-
tion between RSSA upregulation in cancer cells and their 
invasive phenotype has also been reported.38 Consistently, the 
expression of RSSA has been found to be higher in SCLC than 
in NSCLC37 and to be a predictor of poor prognosis in many 
cancers, including NSCLC.39 However, the higher expression 
of RSSA in SCLC than in NSCLC and the prognostic value of 
RSSA were not verified in our study. These discordant results 
may be related to differences in methodologies and antibodies 
used to evaluate RSSA expression or to sample size issues.
We specifically focused on MAPs because of their 
potential as diagnostic or therapeutic target. Yet, cell surface 
proteins are often poorly represented in two-dimensional gels 
due to their hydrophobic nature and high molecular weight.40 
Therefore, this study probably underestimated the number of 
MAPs important for SCLC progression. By restricting our 
study to MAPs, we omitted proteins potentially relevant to 
SCLC biology. Moreover, potentially relevant proteins with 
high expression level did not fulfil our three selection criteria, 
leaving aside other potential candidate biomarkers (available 
in Table 1). Another limitation of the study is the small number 
of cell lines used for the DIGE analysis, although the results 
were validated in a larger group of tumors from patients with 
SCLC and NSCLC. Of note, the mutation status of the cell 
lines may have limited the generalizability of the findings. We 
therefore searched the Sanger Center database (http://cancer.
sanger.ac.uk/cancergenome/projects/cosmic/) for the muta-
tion status of well-known oncogenes or tumor suppressor 
genes in the cell lines we used. We found that none of them 
had AKT1, EGFR, v-Raf Murine sarcoma viral oncogene 
homolog B, MAP2K4, MET, Myc, or NRAS mutation, while 
KRAS mutation was found in  NCI-H23, PIK3CA mutation 
in NCI-H69, PTEN mutation in NCI-H23, retinoblastoma 1 
mutation in all the three SCLC cell lines, and TP53 mutation 
in  NCI-H69, NCI-H209, NCI-H23, and NCI-H520. To the 
exception of retinoblastoma 1 mutation found in all the SCLC 
cell lines (reported in >90% of SCLCs), no other mutation 
was found in every cell line of the same histological subgroup.
In summary, using DIGE coupled with tandem MS to 
analyze a membrane-associated subproteome, we identified 
137 proteins differentially expressed in SCLC compared with 
NSCLC and INBE cells. These proteins were enriched for cel-
lular/tissue morphology networks. DPYL2, GNAQ, RUVB1, 
and STMN1 overexpression in SCLC was verified by WB and/
or IHC, suggesting that these results need to be tested for func-
tional implication in SCLC progression. The association with 
survival requires further validation in larger clinical data sets.
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